INTRODUCTION: P6 outer membrane protein is one of the candidates for a vaccine formulation against nontypeable Haemophilus influenzae (NTHi) infection. As otitis-prone children who have recurrent episodes of acute otitis media because of NTHi show an impaired immune response to P6, an innovative approach to vaccination is required to augment their immune response. RESULTS AND DISCUSSION: We previously identified human HLA-DR9-restricted T cell epitope peptide and highly immunogenic analog peptides on P6 for peptide vaccine candidates. To develop a vaccine formulation effective in the general population, we identified promiscuous T cell epitope peptides (p41-55, p71-85) on P6. In addition to stimulating with potentially promiscuous peptides (p30-44, p45-59) selected using a computer algorithm, we established peptide-specific T cell lines which respond to P6. CONCLUSION: Our present results indicate that these peptides would be candidates for a widely applicable peptide vaccine formulation.
INTRODUCTION: P6 outer membrane protein is one of the candidates for a vaccine formulation against nontypeable Haemophilus influenzae (NTHi) infection. As otitis-prone children who have recurrent episodes of acute otitis media because of NTHi show an impaired immune response to P6, an innovative approach to vaccination is required to augment their immune response. RESULTS AND DISCUSSION: We previously identified human HLA-DR9-restricted T cell epitope peptide and highly immunogenic analog peptides on P6 for peptide vaccine candidates. To develop a vaccine formulation effective in the general population, we identified promiscuous T cell epitope peptides (p41-55, p71-85) on P6. In addition to stimulating with potentially promiscuous peptides (p30-44, p45-59) selected using a computer algorithm, we established peptide-specific T cell lines which respond to P6. CONCLUSION: Our present results indicate that these peptides would be candidates for a widely applicable peptide vaccine formulation.
Authors: M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney Journal: Infect Immun Date: 2001-08 Impact factor: 3.441
Authors: Y Kurono; M Suzuki; G Mogi; M Yamamoto; K Fujihashi; J R McGhee; H Kiyono Journal: Int J Pediatr Otorhinolaryngol Date: 1999-10-05 Impact factor: 1.675
Authors: K W Beagley; J H Eldridge; F Lee; H Kiyono; M P Everson; W J Koopman; T Hirano; T Kishimoto; J R McGhee Journal: J Exp Med Date: 1989-06-01 Impact factor: 14.307
Authors: Amit A Lugade; Paul N Bogner; Thomas H Thatcher; Patricia J Sime; Richard P Phipps; Yasmin Thanavala Journal: J Immunol Date: 2014-04-21 Impact factor: 5.422
Authors: T Yoshizaki; N Bandoh; S Ueda; H Nozawa; T Goto; K Kishibe; M Takahara; Y Harabuchi Journal: Clin Exp Immunol Date: 2009-07 Impact factor: 4.330
Authors: Amit A Lugade; Anna Bianchi-Smiraglia; Vandana Pradhan; Galina Elkin; Timothy F Murphy; Yasmin Thanavala Journal: PLoS One Date: 2011-05-17 Impact factor: 3.240